New trial aims to make stem cell transplants safer for blood cancer patients

NCT ID NCT03970096

First seen Nov 01, 2025 · Last updated Jun 14, 2026 · Updated 31 times

Summary

This study tests two different methods to lower the risk of graft-versus-host disease (GVHD), a serious complication where donor cells attack the patient's body, after a stem cell transplant. About 120 adults with acute leukemia or myelodysplastic syndrome (MDS) in remission will receive either a special filtering of donor cells or a drug called cyclophosphamide after transplant. The goal is to see which approach better prevents severe GVHD and relapse, helping patients live longer with fewer side effects.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE LYMPHOBLASTIC LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Fred Hutch/University of Washington Cancer Consortium

    RECRUITING

    Seattle, Washington, 98109, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Moffitt Cancer Center

    RECRUITING

    Tampa, Florida, 33612, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • University of Pittsburgh Cancer Institute (UPCI)

    RECRUITING

    Pittsburgh, Pennsylvania, 15232, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

Conditions

Explore the condition pages connected to this study.